• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nova Mentis Life Sciences Corp (OP: NMLSF )

    0.0082 +0.0011 (+15.49%)
    Streaming Delayed Price Updated: 3:06 PM EDT, Aug 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,500
    Open 0.0073
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.0071
    Today's Range 0.0073 - 0.0082
    52wk Range 0.0071 - 0.0281
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
    Via Benzinga
    Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
    The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < 
    Via Benzinga

    Performance

    YTD
    -35.43%
    -35.43%
    1 Month
    -31.67%
    -31.67%
    3 Month
    -35.43%
    -35.43%
    6 Month
    -47.10%
    -47.10%
    1 Year
    -64.96%
    -64.96%

    More News

    Read More
    Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
    Via Benzinga
    Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
    Via Benzinga
    Nova Mentis Is Looking To Treat Autism With Psilocybin
    Via Benzinga
    First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
    Via Benzinga
    Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
    Via Benzinga
    Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
    Via Benzinga
    Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
    Via Benzinga
    Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
    Via Benzinga
    Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
    Via Benzinga
    Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
    Via Newsfile
    New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
    Via Benzinga
    Nova Mentis Completes Production of Psilocybin Microdose Capsules
    Via Newsfile
    More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
    Via Benzinga
    Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
    Via Benzinga
    Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
    Via Benzinga
    Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
    Via Benzinga
    This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
    Via Benzinga
    Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
    Via Benzinga
    Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
    Via Benzinga
    Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
    Via Benzinga
    Exposures Product Safety
    Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
    Via Benzinga
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    Via Benzinga
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.